Market Cap 4.48B
Revenue (ttm) 2.04M
Net Income (ttm) -162.34M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -7,957.84%
Debt to Equity Ratio 0.00
Volume 2,478,100
Avg Vol 750,026
Day's Range N/A - N/A
Shares Out 54.67M
Stochastic %K 84%
Beta 1.18
Analysts Strong Sell
Price Target $127.85

Company Profile

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneousl...

Industry: Biotechnology
Sector: Healthcare
Phone: 929 999 4055
Address:
7 Times Square, 43rd Floor, New York, United States
topstockalerts
topstockalerts Jun. 13 at 1:28 AM
$DNTH this stock is slowly forcing its way onto the radar.
0 · Reply
StocktwitsNews
StocktwitsNews Jun. 12 at 9:13 PM
DNTH Stock Clocks Best Day In Over 3 Months On Strong Nerve Disorder Study Results $DNTH $SNY https://stocktwits.com/news/equity/markets/dnth-stock-clocks-best-day-in-over-3-months-on-strong-nerve-disorder-study-results/cZKd9QHR75h
0 · Reply
notreload_ai
notreload_ai Jun. 12 at 8:20 PM
Raymond James reiterated its Strong Buy rating and $125 price target on $DNTH after the company reported strong early data from the Phase 3 CAPTIVATE study of claseprubart in CIDP. https://notreload.xyz/xy/raymond-james-bullish-on-dianthus-as-claseprubart-outperforms-expectations/
0 · Reply
Quantumup
Quantumup Jun. 12 at 7:40 PM
Raymond James reiterated $DNTH Strong Buy; $125 $SNY $ARGX JNJ IMVT - ROIV RNAC KYTX VRTX AZN Here's what Raymond James said: https://x.com/Quantumup1/status/2065519020451708994?s=20
0 · Reply
garygb
garygb Jun. 10 at 7:14 PM
$DNTH Clealy oversold - turning up now.
0 · Reply
Quantumup
Quantumup Jun. 10 at 3:51 PM
Stifel on $DNTH (Buy; $120) said: $SNY announced this morning that they are discontinuing the MOBILIZE Ph3 of Riliprubart in CIDP patients refractory to IVIg. JNJ ARGX IMVT - ROIV $RNAC KYTX VRTX AZN here's what Stifel went on to say: https://x.com/Quantumup1/status/2064736580997177623?s=20
0 · Reply
justiceforb_85
justiceforb_85 Jun. 10 at 3:22 PM
$DNTH sell off overdone. Adding.
0 · Reply
theflynews
theflynews Jun. 10 at 1:25 PM
Pre-Market Fly By for Wednesday, June 10th: Breaking Stock Market News $SMCI $CHWY $CBRL $HNGE $DNTH
0 · Reply
DonCorleone77
DonCorleone77 Jun. 10 at 1:13 PM
$CHWY $LAKE $DNTH $SMCI $NKE PRE-MARKET MOVERS: Currently Higher After Earnings: - Yuanbao (YB) up 16.8% - Cracker Barrel (CBRL) up 15.6% - Lakeland Industries (LAKE) up 9.4% - Core & Main (CNM) up 1.0% Currently Also Higher: - Cava Group (CAVA) up 2.3% after UBS upgraded the stock to Buy with a price target of $90, up from $85 - Hinge Health (HNGE) up 4.6% after raising its Q2 and FY26 revenue outlook at its inaugural investor day Currently Lower After Earnngs: - Chewy (CHWY) down 4.7% - J.Jill (JILL) down 0.3% Currently Also Lower: - Dianthus (DNTH) down 19.4% after peer Sanofi (SNY) announced that its riliprubart Phase 3 study in patients with chronic inflammatory demyelinating polyneuropathy will be stopped - Super Micro (SMCI) down 12.2% after announcing a series of concurrent equity and equity-linked financing transactions totaling $7B, in expected aggregate amount as part of its plan to fund the purchase of components to satisfy the AI orders that the company has received in recent weeks for its advanced AI servers - Nike (NKE) down 1.3% after RBC Capital downgraded shares to Sector Perform with a price target of $50, down from $70
0 · Reply
Arcides
Arcides Jun. 10 at 12:24 PM
$DNTH to touch 63
0 · Reply
Latest News on DNTH
Dianthus rises 7.7%

2026-06-12T16:08:04.000Z - 6 days ago

Dianthus rises 7.7%


Dianthus falls -16.0%

2026-06-10T16:07:44.000Z - 8 days ago

Dianthus falls -16.0%


Dianthus falls -13.7%

2026-06-10T14:00:12.000Z - 8 days ago

Dianthus falls -13.7%


Dianthus sinks after Sanofi halts CIDP Phase 3 study

2026-06-10T11:33:17.000Z - 8 days ago

Dianthus sinks after Sanofi halts CIDP Phase 3 study

SNY


Dianthus reports Q1 EPS (85c), consensus ($1.10)

2026-05-05T20:18:38.000Z - 6 weeks ago

Dianthus reports Q1 EPS (85c), consensus ($1.10)


Dianthus Therapeutics Earnings release: Q1 2026

May 5, 2026, 4:00 PM EDT - 6 weeks ago

Dianthus Therapeutics Earnings release: Q1 2026


Dianthus Therapeutics Quarterly report: Q1 2026

May 5, 2026, 4:00 PM EDT - 6 weeks ago

Dianthus Therapeutics Quarterly report: Q1 2026


Dianthus Therapeutics Slides: Corporate presentation

May 5, 2026, 4:00 PM EDT - 6 weeks ago

Dianthus Therapeutics Slides: Corporate presentation


Dianthus treatment of myasthenia gravis gets orphan status

2026-05-01T14:58:27.000Z - 6 weeks ago

Dianthus treatment of myasthenia gravis gets orphan status


Dianthus Therapeutics Proxy statement: Proxy filing

Apr 9, 2026, 8:00 AM EDT - 2 months ago

Dianthus Therapeutics Proxy statement: Proxy filing


Dianthus Therapeutics Proxy statement: Proxy filing

Apr 9, 2026, 8:00 AM EDT - 2 months ago

Dianthus Therapeutics Proxy statement: Proxy filing


Dianthus initiated with an Outperform at Wolfe Research

2026-04-08T20:41:37.000Z - 2 months ago

Dianthus initiated with an Outperform at Wolfe Research

SNY


Dianthus Therapeutics Slides: Corporate presentation

Mar 26, 2026, 7:00 AM EDT - 3 months ago

Dianthus Therapeutics Slides: Corporate presentation


Dianthus initiated with an Overweight at Wells Fargo

2026-03-19T10:00:52.000Z - 3 months ago

Dianthus initiated with an Overweight at Wells Fargo


Dianthus price target raised to $103 from $80 at Wedbush

2026-03-12T12:37:41.000Z - 3 months ago

Dianthus price target raised to $103 from $80 at Wedbush


Dianthus Therapeutics Transcript: Study result

Mar 9, 2026, 8:00 AM EDT - 3 months ago

Dianthus Therapeutics Transcript: Study result


Dianthus Therapeutics Press release: Study result

Mar 9, 2026, 8:00 AM EDT - 3 months ago

Dianthus Therapeutics Press release: Study result


Dianthus Therapeutics Slides: Study result

Mar 9, 2026, 8:00 AM EDT - 3 months ago

Dianthus Therapeutics Slides: Study result


Dianthus Therapeutics Earnings release: Q4 2025

Mar 9, 2026, 7:00 AM EDT - 3 months ago

Dianthus Therapeutics Earnings release: Q4 2025


Dianthus Therapeutics Annual report: Q4 2025

Mar 9, 2026, 7:00 AM EDT - 3 months ago

Dianthus Therapeutics Annual report: Q4 2025


Dianthus Therapeutics Slides: Corporate presentation

Jan 12, 2026, 7:00 AM EST - 5 months ago

Dianthus Therapeutics Slides: Corporate presentation


Dianthus Therapeutics Slides: Corporate Presentation

Dec 2, 2025, 4:00 PM EST - 7 months ago

Dianthus Therapeutics Slides: Corporate Presentation


Dianthus Therapeutics Slides: Corporate Presentation

Nov 10, 2025, 6:00 PM EST - 7 months ago

Dianthus Therapeutics Slides: Corporate Presentation


Dianthus Therapeutics Earnings release: Q3 2025

Nov 5, 2025, 7:00 AM EST - 8 months ago

Dianthus Therapeutics Earnings release: Q3 2025


Dianthus Therapeutics Quarterly report: Q3 2025

Nov 5, 2025, 7:00 AM EST - 8 months ago

Dianthus Therapeutics Quarterly report: Q3 2025


Dianthus Therapeutics Transcript: Study Update

Oct 16, 2025, 8:00 AM EDT - 8 months ago

Dianthus Therapeutics Transcript: Study Update


Dianthus Therapeutics Press release: Study Update

Oct 16, 2025, 8:00 AM EDT - 8 months ago

Dianthus Therapeutics Press release: Study Update


Dianthus Therapeutics Slides: Study Update

Oct 16, 2025, 8:00 AM EDT - 8 months ago

Dianthus Therapeutics Slides: Study Update


Dianthus Therapeutics Slides: Corporate Presentation

Oct 3, 2025, 7:00 AM EDT - 9 months ago

Dianthus Therapeutics Slides: Corporate Presentation


Dianthus Therapeutics Transcript: Study Result

Sep 8, 2025, 8:00 AM EDT - 10 months ago

Dianthus Therapeutics Transcript: Study Result


Dianthus Therapeutics Press release: Study Result

Sep 8, 2025, 8:00 AM EDT - 10 months ago

Dianthus Therapeutics Press release: Study Result


Dianthus Therapeutics Slides: Study Result

Sep 8, 2025, 8:00 AM EDT - 10 months ago

Dianthus Therapeutics Slides: Study Result


Dianthus Therapeutics Earnings release: Q2 2025

Aug 7, 2025, 7:00 AM EDT - 11 months ago

Dianthus Therapeutics Earnings release: Q2 2025


Dianthus Therapeutics Quarterly report: Q2 2025

Aug 7, 2025, 7:00 AM EDT - 11 months ago

Dianthus Therapeutics Quarterly report: Q2 2025


Dianthus Therapeutics Earnings release: Q1 2025

May 12, 2025, 4:00 PM EDT - 1 year ago

Dianthus Therapeutics Earnings release: Q1 2025


Dianthus Therapeutics Quarterly report: Q1 2025

May 12, 2025, 4:00 PM EDT - 1 year ago

Dianthus Therapeutics Quarterly report: Q1 2025


Dianthus Therapeutics Proxy statement: Proxy Filing

Apr 10, 2025, 8:00 AM EDT - 1 year ago

Dianthus Therapeutics Proxy statement: Proxy Filing


Dianthus Therapeutics Proxy statement: Proxy Filing

Apr 10, 2025, 8:00 AM EDT - 1 year ago

Dianthus Therapeutics Proxy statement: Proxy Filing


Dianthus Therapeutics Annual report: Q4 2024

Mar 11, 2025, 4:00 PM EDT - 1 year ago

Dianthus Therapeutics Annual report: Q4 2024


Dianthus Therapeutics Earnings release: Q4 2024

Mar 11, 2025, 4:00 PM EDT - 1 year ago

Dianthus Therapeutics Earnings release: Q4 2024


Dianthus Therapeutics Quarterly report: Q3 2024

Nov 7, 2024, 4:00 PM EST - 1 year ago

Dianthus Therapeutics Quarterly report: Q3 2024


Dianthus Therapeutics Earnings release: Q3 2024

Nov 7, 2024, 4:00 PM EST - 1 year ago

Dianthus Therapeutics Earnings release: Q3 2024


Dianthus Therapeutics Quarterly report: Q2 2024

Aug 8, 2024, 5:00 PM EDT - 2 years ago

Dianthus Therapeutics Quarterly report: Q2 2024


Dianthus Therapeutics Earnings release: Q2 2024

Aug 8, 2024, 5:00 PM EDT - 2 years ago

Dianthus Therapeutics Earnings release: Q2 2024


Dianthus Therapeutics Quarterly report: Q1 2024

May 9, 2024, 7:00 AM EDT - 2 years ago

Dianthus Therapeutics Quarterly report: Q1 2024


Dianthus Therapeutics Earnings release: Q1 2024

May 9, 2024, 7:00 AM EDT - 2 years ago

Dianthus Therapeutics Earnings release: Q1 2024


Dianthus Therapeutics Proxy statement: Proxy Filing

Apr 11, 2024, 8:00 AM EDT - 2 years ago

Dianthus Therapeutics Proxy statement: Proxy Filing


Dianthus Therapeutics Proxy statement: Proxy Filing

Apr 11, 2024, 8:00 AM EDT - 2 years ago

Dianthus Therapeutics Proxy statement: Proxy Filing


Dianthus Therapeutics Annual report: Q4 2023

Mar 21, 2024, 8:00 AM EDT - 2 years ago

Dianthus Therapeutics Annual report: Q4 2023


Dianthus Therapeutics Earnings release: Q4 2023

Mar 21, 2024, 8:00 AM EDT - 2 years ago

Dianthus Therapeutics Earnings release: Q4 2023


Dianthus Therapeutics Slides: Corporate Presentation

Mar 14, 2024, 10:00 AM EDT - 2 years ago

Dianthus Therapeutics Slides: Corporate Presentation


Dianthus Therapeutics Quarterly report: Q3 2023

Nov 9, 2023, 7:00 AM EST - 2 years ago

Dianthus Therapeutics Quarterly report: Q3 2023


Dianthus Therapeutics Earnings release: Q3 2023

Nov 9, 2023, 7:00 AM EST - 2 years ago

Dianthus Therapeutics Earnings release: Q3 2023


topstockalerts
topstockalerts Jun. 13 at 1:28 AM
$DNTH this stock is slowly forcing its way onto the radar.
0 · Reply
StocktwitsNews
StocktwitsNews Jun. 12 at 9:13 PM
DNTH Stock Clocks Best Day In Over 3 Months On Strong Nerve Disorder Study Results $DNTH $SNY https://stocktwits.com/news/equity/markets/dnth-stock-clocks-best-day-in-over-3-months-on-strong-nerve-disorder-study-results/cZKd9QHR75h
0 · Reply
notreload_ai
notreload_ai Jun. 12 at 8:20 PM
Raymond James reiterated its Strong Buy rating and $125 price target on $DNTH after the company reported strong early data from the Phase 3 CAPTIVATE study of claseprubart in CIDP. https://notreload.xyz/xy/raymond-james-bullish-on-dianthus-as-claseprubart-outperforms-expectations/
0 · Reply
Quantumup
Quantumup Jun. 12 at 7:40 PM
Raymond James reiterated $DNTH Strong Buy; $125 $SNY $ARGX JNJ IMVT - ROIV RNAC KYTX VRTX AZN Here's what Raymond James said: https://x.com/Quantumup1/status/2065519020451708994?s=20
0 · Reply
garygb
garygb Jun. 10 at 7:14 PM
$DNTH Clealy oversold - turning up now.
0 · Reply
Quantumup
Quantumup Jun. 10 at 3:51 PM
Stifel on $DNTH (Buy; $120) said: $SNY announced this morning that they are discontinuing the MOBILIZE Ph3 of Riliprubart in CIDP patients refractory to IVIg. JNJ ARGX IMVT - ROIV $RNAC KYTX VRTX AZN here's what Stifel went on to say: https://x.com/Quantumup1/status/2064736580997177623?s=20
0 · Reply
justiceforb_85
justiceforb_85 Jun. 10 at 3:22 PM
$DNTH sell off overdone. Adding.
0 · Reply
theflynews
theflynews Jun. 10 at 1:25 PM
Pre-Market Fly By for Wednesday, June 10th: Breaking Stock Market News $SMCI $CHWY $CBRL $HNGE $DNTH
0 · Reply
DonCorleone77
DonCorleone77 Jun. 10 at 1:13 PM
$CHWY $LAKE $DNTH $SMCI $NKE PRE-MARKET MOVERS: Currently Higher After Earnings: - Yuanbao (YB) up 16.8% - Cracker Barrel (CBRL) up 15.6% - Lakeland Industries (LAKE) up 9.4% - Core & Main (CNM) up 1.0% Currently Also Higher: - Cava Group (CAVA) up 2.3% after UBS upgraded the stock to Buy with a price target of $90, up from $85 - Hinge Health (HNGE) up 4.6% after raising its Q2 and FY26 revenue outlook at its inaugural investor day Currently Lower After Earnngs: - Chewy (CHWY) down 4.7% - J.Jill (JILL) down 0.3% Currently Also Lower: - Dianthus (DNTH) down 19.4% after peer Sanofi (SNY) announced that its riliprubart Phase 3 study in patients with chronic inflammatory demyelinating polyneuropathy will be stopped - Super Micro (SMCI) down 12.2% after announcing a series of concurrent equity and equity-linked financing transactions totaling $7B, in expected aggregate amount as part of its plan to fund the purchase of components to satisfy the AI orders that the company has received in recent weeks for its advanced AI servers - Nike (NKE) down 1.3% after RBC Capital downgraded shares to Sector Perform with a price target of $50, down from $70
0 · Reply
Arcides
Arcides Jun. 10 at 12:24 PM
$DNTH to touch 63
0 · Reply
notreload_ai
notreload_ai Jun. 10 at 11:02 AM
$SNY discontinues its Phase 3 MOBILIZE study of riliprubart in refractory CIDP after failing to show efficacy. The setback raises major doubts for $DNTH claseprubart (C1s inhibitor). https://notreload.xyz/xy/sanofi-drops-phase-3-riliprubart-trial-in-cidp-dianthus-plunges/
0 · Reply
mryangstock
mryangstock Jun. 5 at 8:11 PM
$SRXH $DNTH https://youtube.com/shorts/TGsbIXg5WUs?feature=share There are times the market only reprices and re-rates a stock after the actual merger. SRXH is still in pre-merger action. I still see it being re-rated as its actual value is way higher than the current pre-merger price, just like DNTH.
0 · Reply
CapitalMonk
CapitalMonk Jun. 3 at 11:55 AM
$DNTH Price: $81.57 (-8.81%) Trend: Bullish Market Bias (7D): Bullish Bias 📈 Expected Range: ±3.03% RSI: 42.8 | Momentum: Moderate Volume: +84.8% vs avg Volatility: 3.20% Support: $80.32 | Resistance: $93.61 Data and analytics sourced from Given Analytics educational research: https://www.givenanalytics.com/
0 · Reply
StockConsultant
StockConsultant Jun. 1 at 12:35 PM
$DNTH Dianthus Therapeutics stock, good day, watch for a narrow range breakout at https://stockconsultant.com/?DNTH Breakout trade WATCH for possible breakout above 95.94 Target: 109.03, 17.2% Stop: 87.9 Loss: 5.5% P/L ratio: 3.1 : 1 - Excellent BULLISH [Timing] Strong bullish 3 day candlestick pattern with Good 3 day accumulation. [Timing] Extreme bullish 1 day moneyflow [Timing] breakout watch above 95.94, no resistance in area just above. BEARISH [Positioning] Intermediate trend possibly bearish, Uptrend turned sideways, may continue or pullback. [Positioning] at resistance
0 · Reply
Doozio
Doozio May. 30 at 3:04 PM
$DNTH out of the tightness as XBI dropped da 🪧 ONTA 🐒🍌🧠⏰♾️
0 · Reply
Avocado_smash
Avocado_smash May. 29 at 1:25 PM
$DNTH Structure and Trend strength up>
0 · Reply
justiceforb_85
justiceforb_85 May. 19 at 4:42 AM
$DNTH added. Claseprubart will be best in class C1s inhibitor. DNTH212 first in class BDCA2/APRIL+BAFF inhibitor with likely better efficacy than litifilimab.
0 · Reply
BillionerOfKing
BillionerOfKing May. 2 at 2:56 AM
$DNTH Current Stock Price: $87.31 Contracts to trade: $85.0 DNTH May 15 2026 Call Entry: $3.90 Exit: $6.77 ROI: 74% Hold ~22 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Tgk11
Tgk11 May. 1 at 12:21 AM
$DNTH Buyout number $200
0 · Reply
NJgolfer
NJgolfer Apr. 30 at 10:35 PM
$DNTH likelihood of choppy sideways action for awhile, between $76 - $88. This is up 255% over last 8 months so time for a rest. I am long-term holding and see multiple extensions out to $111 area. Just being patient...
0 · Reply
Avocado_smash
Avocado_smash Apr. 15 at 11:59 PM
$DNTH Structure and Trend strength up>
0 · Reply